If you are interested in participating in a research study please click the link below, or call (773) 388-8880 to inquire about current opportunities. 

Click here to participate in a research study.

We are currently seeking participants for the following studies:

The Smoking Research Project

The Smoking Research Project is currently recruiting HIV+, African American men who have sex with men, ages 21 and over, who currently smoke and want to quit smoking to participate in a one-time focus group with a brief questionnaire.
Participants will be compensated for time and travel.

For more information, please call 773-388-8880.

C-TALK

For guys who have done drugs and love sex.
 
Come to a ten-week group focused on healthy sexuality for men who have used cocaine and crystal meth.  This is a research study conducted by the University of Illinois at Chicago (UIC) and Howard Brown Health Center to see if groups like this one can help men develop a healthier sense of sexuality that doesn't always depend on using drugs.
 
For more information, please contact:
Nicole Perez at 773-388-8872, or nicolep@howardbrown.org.

TWISTA (TransWomen Informing Sister TransWomen on AIDS)
 
Hmmmm... Wonder where you can go to talk to people just like you? Would you like to attend our programs for young transgender women ages 16-24? We will be talking about issues related to you and your life. Those who join will be reimbursed for their time. To find out more contact us @ 1773-935-3151 ext 281 or nicolep@howardbrown.org

TWISTA Love is STRONG!!!
TWISTA Love is SAFE!!!
TWISTA Love is SURVIVING!!!

PROJECT ICARE

Are you an African American man who has sex with men?
Do you want to participate in a research study?
Contact us to see if you qualify.
Please call 773-388-8880 for more information.

MyPeeps

* Are you between the ages of 16 and 20?
* Are you a guy who has sex with other guys?

If you answered “yes” to both questions, you may be eligible to join our research project. 
We are looking for young men to take part in a series of group sessions about sexual health, including HIV.

Those who join will be reimbursed for their time.

To find out more please call us at 773.388-8880 or email: mypeeps@howardbrown.org.

ICE-001
ICE-001 is a Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based versus an Efavirenz-Based HAART Regimen in HIV-Infected Subjects.  Participants receive study medication and lab work at no charge and are compensated for time and travel. 

Enrollment is currently open.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Pfizer A4001067
Pfizer A4001067 is an International, Multicenter, Prospective Observational Study of the Safety of Maraviroc used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients.   Participants will be compensated for time and travel. 

Enrollment is currently open.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

GS US 236-0103 
GS US 236-0103 is a Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Elvitegravir/ Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults.  Participants may receive study medication and lab work at no charge and are compensated for time and travel.

Enrollment is currently open.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

GS US 216-0114 
GS US 216-0114is a Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 infected, Antiretroviral Treatment-Naïve Adults.  Participants may receive study medication and lab work at no charge and are compensated for time and travel.

Enrollment is currently open.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

GSK EPZ113734
GSK EPZ113734 is a Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine Without Ritonavir for 48 Weeks in Virologically Suppressed, HIV-1 Infected, HLAB* 5701 Negative Subjects.  Participants may receive study medication and lab work at no charge and are compensated for time and travel.

Enrollment is currently open.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.